skip to main content
Back to all blog posts

Posted in: Intellectual Property | Upcoming Events

Feb 7, 2017

Complimentary Webinar - Canadian Pharma Update: Patent Law

Join us for a complimentary webinar on Thursday, February 9 from 9 - 10 a.m. regarding upcoming changes to the Canadian patent regime. The top 10 Canadian patent developments of concern to pharmaceutical companies will be discussed, including:

  • Supreme Court of Canada considers utility requirements - defining the "Promise"
  • Validity of biologic patents
  • Upcoming legislative implementation of CETA, including two-year patent extensions
  • Patented Medicines Prices Review Board - review of orphan drug pricing

Click here to register


Paula Bremner is a lawyer and member of  Aird & Berlis LLP's Litigation Group and Intellectual Property Group. She is a registered Canadian patent and trademark agent. Paula specializes in pharmaceutical patent litigation, particularly in the context of the Patented Medicines (Notice of Compliance) Regulations.



Kimberly McManus, (Ph.D.) is a registered patent agent and member of Aird & McBurney LP. She specializes in patent protection and enforcement issues for the pharmaceutical and chemical industries.



CPD for Lawyers: 1 Substantive Hour


Related Blogs

Posted in: Intellectual Property | Court Decision

Insights TheSpotlight
Protection of Rights in Canada and International Comity Supreme Court of Canada Plants its Flag Down By Paige Backman, Aaron Baer and Codie Mitchell Jul 13, 2017 The Supreme Court of Canada’s recent and much-anticipated decision in Google Inc. v. Equustek Solutions Inc. is extremely important for many reasons. It has been applauded by Canadian companies whose intellectual property rights are being infringed by overseas companies, but, it has left ma...

Posted in: Intellectual Property

Insights TheSpotlight
Supreme Court of Canada Holds Promise of Utility Doctrine Incongruent with Patent Act AstraZeneca Canada Inc. et al. v. Apotex Inc. et al., 2017 SCC 36 By Kitt Sinden, M.Sc. Jun 30, 2017 Reasons for Judgement: Rowe J. (McLachlin, Abella, Moldaver, Karakatsanis, Wagner, Gascon, Côté and Brown concurring) On appeal from a judgment of the Federal Court of Appeal (2015 FCA 158) affirming a decision of Rennie J. (2014 FC 638) AstraZeneca applied for the 2,139,653 patent (...

Posted in: TheSpotlight Categories | Intellectual Property

Insights TheSpotlight
Canadian Court of Appeal has Something to Say on Obviousness: Critical of Rigid Tests and Using a Solution-Based Identification of the Inventive Concept that Excludes Serendipitous Discoveries Means Atazanavir Salt Obvious By Kitt Sinden, M.Sc. May 08, 2017 The Federal Court of Appeal (“FCA”) recently affirmed a Federal Court (“FC”) finding that an antiviral salt was obvious, although based on different reasoning1. The FCA provided a detailed analysis of the “inventive concept” (“IC”), although it is arguably still unclear as to when/why it is appro...